ImmuPharma (LON:IMM) Trading Up 27.3% - Here's Why

Key Points

• Shares of ImmuPharma plc surged by 27.3% during trading, reaching a last traded price of GBX 12.60 ($0.17), despite a significant decline in share volume.
• The company reported a negative P/E ratio of -1,415.73 and an anticipated EPS of -339.0000022 for the current fiscal year, highlighting ongoing financial challenges.
• ImmuPharma specializes in developing peptide-based therapeutics for autoimmune diseases, with its lead program, Lupuzor™, targeting Lupus and potentially other similar conditions.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price shot up 27.3% during mid-day trading on Saturday . The company traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). 4,543,810 shares traded hands during mid-day trading, a decline of 46% from the average session volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Stock Performance

The business's 50 day moving average is GBX 7.92 and its 200-day moving average is GBX 4.36. The stock has a market cap of £63.34 million, a price-to-earnings ratio of -1,415.73 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Sell-side analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.